Introduction
Fetal or neonatal alloimmune thrombocytopenia (FNAIT) is a potentially life-threatening disease where the fetal platelets are targeted by maternal anti-platelet IgG alloantibodies crossing the placenta. This leads to FcγR-mediated uptake by phagocytes in the fetal spleen and liver, finally resulting in thrombocytopenia. 1 Clinical outcome may differ from asymptomatic, to petechiae, or intracerebral hemorrhage. The strength of the interaction between IgG and FcγR depends on several factors, including the IgG subclass formed during the immune response, their relative affinity to FcγRs, the expression levels of FcγR allotypes, FcγR copy number variation, cytokines (influencing the expression of FcγR) but also the IgG Fc glycosylation pattern. 2 IgG antibodies are glycoproteins containing a branched sugar moiety attached to the asparagine (Asn)297 residue in the Fc part. This glycan is essential for the maintenance of a functional structure and for binding of IgG with FcγR. [3] [4] [5] In addition, the Asn297-linked glycans are substituted with variable amounts of galactose, sialic acid and may additionally carry a bisecting N-acetylglucosamine (GlcNAc) and core fucose. Variation in this composition influences antibody affinity to FcγR and thus antibody effector activity. IgG galactosylation has been found to be decreased in several inflammatory diseases (primary osteoarthritis, rheumatoid arthritis, tuberculosis) 6;7 as well as in ovarian cancer. 8 Interestingly, increase in galactosylation correlates with remission of arthritis in pregnant rheumatoid arthritis patients. 7;9;10 The degree of IgG galactosylation has been shown to depend on age and gender, as IgG-galactosylation is higher in females at young age, and decreases for both males and females with increasing age. 11;12 In addition, an increase for total IgG-galactosylation has been observed in pregnancy. 7;9;10;13 Recently, an anti-inflammatory activity of immune complexes containing highly Fc-galactosylated mouse IgG1 was reported to enhance the association of FcγRIIb with dectin-1. 14 Changes related to age, gender and pregnancy have also been described for IgG sialylation. Sialylation slightly reduces the affinity of IgG to FcγRs, but enhances the binding to Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), thereby leading to an anti-inflammatory response due to increased expression of the inhibitory FcγRIIb. 15 ; 16 17 Importantly, a lack of core fucose has been demonstrated to result in a stronger binding affinity to FcγRIIIa and FcγRIIIb, due to glycan-glycan interactions between Asn162 found only in FcγRIII and Asn297 in IgG1. 18,5;19 Curiously, although non-fucosylated antibodies clearly enhance the binding to FcγRIIIa and FcγRIIIb, this only results in enhanced antibody dependent cellular cytotoxicity (ADCC) on mononuclear cells through FcγRIIIa, 3, [20] [21] [22] [23] [24] but not through the GPI linked FcγRIIIb on polymorphonuclear (PMN) cells. 18 ; 25 The therapeutic anti-cancer potential of antibodies with decreased fucosylation however, has been well recognized and their power is currently being harnessed in clinical trials. 18;20-24;26-30 In Caucasians, the main antibodies causing FNAIT are the anti-human platelet antigen (HPA)-1a antibodies, found in about 85% of the cases and in approximately 1:1500 pregnancies. [31] [32] [33] The HPA-1a epitope resides in the GPIIIa protein of the GPIIb/IIIa complex, and is missing in individuals with a single nucleotide polymorphism (SNP) resulting in a L to P change at position 33 in the mature protein. 31 In a previous study we reported a reduced fucosylation, an increased galactosylation and sialylation of various anti-platelet IgG1 for a small series of FNAIT sera (including two samples with anti-HPA-1a antibodies). 32 We now expand this to a cohort of 48 FNAIT anti-HPA-1a samples. Furthermore, we compare the glycosylation of IgG formed during immune responses against platelets in pregnancy to that of IgG formed against HLA after platelet transfusion or pregnancies. Our main findings show that Fc-fucosylation is decreased in FNAIT, but not in refractory thrombocytopenia (RT), based on Fc-analysis of anti-HPA-1a antibodies as well as anti-HLA class I antibodies, respectively, indicating that Fc-fucosylation is regulated. Decreased Fc-fucosylation increased the IgG affinity to FcγRIIIa and FcγRIIIb and also increased platelet-phagocytosis by both monocytes and neutrophils, a key process in the pathogenesis of FNAIT.
Methods

Patient samples
Anti-HPA-1a platelet alloantibodies were diagnosed at Sanquin, Amsterdam, Netherlands (n=39), at University Hospital North Norway, Tromsø, Norway (n=5) and at NHSBT, Bristol, UK (n=4), from maternal FNAIT sera using a monoclonal antibody immobilization of platelet antigens assay (MAIPA), performed as described by Kiefel et al. 33 The HLA-class I antibodies were all diagnosed at Sanquin, Amsterdam, Netherlands (n=13) and detected in serum from RT-patients (refractory for platelet transfusions), using the Lifescreen Luminex HLA-class I antibody screening method. 34 Patient characteristics for all samples included in the study are listed in Supplementary Table 1 .
Purification of anti-platelet antibodies from sera HPA-1a-specific alloantibodies were purified in a similar way as we described previously 32 , but now instead of eluting from platelets, we increased the specificity by eluting the antibodies with formic acid from antigen-coated plates (PAK12, Immucor GTI Diagnostics, Waukesha, WI, USA). Same plates were used for purification of anti-HLA class I antibodies. Further details are described in the Supplementary methods.
Mass spectrometric IgG Fc glycosylation analysis
Nano liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed as described in the Supplementary methods.
Production of recombinant anti-TNP IgG1 antibodies with low and high amounts of Fc-fucose
The variable regions of the heavy and light chains (VH, VL) of the mouse IgG1 anti-2,4,6-trinitrophenol (TNP) hapten antibodies were cloned onto human IgG1 or kappa backbone, respectively, as described previously, 35 and produced in the HEK-293F FreeStyle cell line expression system (Life technologies, Paisley, UK), but now in the presence or absence of 2-deoxy-2-fluoro-L-fucose (2F; Carbosynth, Compton, Berkshire, UK), to control the level of fucosylation. 36 Antibodies were purified on a protein A (WT IgG1) HiTrap HP column (GE Healthcare Life Sciences, Little Chalfont, UK) using the Acta Prime Plus system (GE Healthcare Life Sciences) and dialyzed against PBS overnight. IgG-Fc glycosylation was determined by mass spectrometry.
Surface Plasmon Resonance (SPR)
Surface Plasmon Resonance (SPR) measurements were performed with the Biacore 3000 system (Biacore AB, Breda, The Netherlands) at 25°C. Anti-Histidine antibody (GE Healthcare, The Netherlands), 25 μg/ml in sodium acetate buffer pH 4.5 (GE Healthcare), was coupled covalently to a CM5 chip (GE Healthcare) following activation with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC, Sigma-Aldrich, Zwijndrecht, The Netherlands) 0.4 M in water and N-hydroxysuccinimide (NHS, Sigma-Aldrich) 0.1 M. To measure binding of monoclonal IgG to FcγRs, 20 ng human recombinant polyHisTag FcγRIIa or 10 ng human recombinant polyHisTag FcγRIIIa (Novoprotein, NJ USA) or 5 ng human recombinant polyHisTag FcγRIIIb (NA2, Sino Biologicals Inc., China), diluted in 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20 (HBS-EP buffer, GE Healthcare), was injected followed by the injection of anti-TNP IgG at different concentration. Further details are described in the supplemental methods.
Cell isolations, TNP-haptenization, labeling and antibody opsonization
Human platelets, PMN and monocytes were isolated freshly, and platelets were haptenized with TNP, as described in the supplemental methods.
Hereafter, platelets were labeled with pHrodo by resuspending a platelet pellet in 0.23 mM pHrodo succinimidyl ester (100 μl/10 8 platelets) (Invitrogen, Molecular Probes, Eugene, Oregon, USA), in 100 ng/mL Prostaglandin E1 (PGE1), for 45 minutes in the dark at room temperature. Then, the platelets were washed twice and re-suspended in PBS/EDTA/PGE1 at 10 8 platelets/ml.
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The haptenized and pHrodo-labeled platelets were opsonized by resuspending a pellet of platelets with 100 µl of 10 µg/ml anti-TNP antibody low/high fucose or isotype antibody for every 10 8 platelets, and subsequent incubation for 30 minutes at room temperature. Hereafter platelets were washed twice with PBS/BSA and resuspended at 10 8 /ml in Normal Human Serum (NHS).
Similarly, unhaptenized and pHrodo-labeled platelets were opsonized by resuspending a pellet of platelets with 100 µl FNAIT-anti-HPA-1a serum diluted to 35 Arbritrary units (AU) of anti-HPA-1a antibody (using a human anti-HPA-1a standard, 100 AU, NIBSC code: 03/152, Hertfordshire, UK), for every 10 8 platelets. NHS was used as isotype control. Hereafter, the platelets were incubated for 30 minutes at room temperature, washed twice with PBS and resuspended at 10 8 /ml in NHS.
Platelet-phagocytosis using anti-TNP antibodies or FNAIT-anti-HPA-1a sera Phagocytosis was carried out using freshly isolated human PMN or CD16 /ml opsonized platelets were mixed in a total volume of 100 µl in 1.4 ml U-bottom tubes (Micronic, Lelystad, The Netherlands), for 20 minutes in a shaking incubator at 37°C. After the reaction, the cells were kept on ice and washed in cold PBS. Samples were measured with a flow cytometer (LSRII, BD Bioscience, San Jose, CA, USA) and analyzed for colored events using FacsDIVA software (BD Bioscience, San Jose, CA, USA). Phagocytosis data was eventually compared to the degree of Fc-fucosylation as determined by mass spectrometry, as described previously.
Results
Fc-glycosylation of anti-HPA-1a antibodies formed in FNAIT Total IgG and anti-HPA-1a antibodies were purified from 48 maternal anti-HPA-1a-FNAIT sera by affinity absorption and elution on HPA-1a containing immunosorbent plates, subjected to tryptic digestion, and the resulting IgG1 Asn297-Fc glycopeptides analyzed by mass spectrometry. No IgG-Fc glycopeptides were detected when NHS (without anti-HPA1a antibodies) was subjected to the anti-HPA-1a purification procedure (data not shown). Likewise, no IgG glycopeptides were detected when anti-HPA-1a FNAIT sera were applied to immunosorbent matrixes containing irrelevant antigens. Together, these experiments demonstrate the specificity of the anti-HPA-1a IgG1 purification procedure. A total of 14 different IgG1 Fc glycopeptides were monitored (Table 1) . For some patients, only small differences in glycosylation profiles of total IgG1 and anti-HPA-1a IgG1 were observed (example of full glycoprofiles in Fig. 1A and B) , while marked differences were observed for others (example in Fig. 1C and D) : For total IgG1, the Fc glycosylation profile were always dominated by fucosylated glycan structures (G0F, G1F, G2F and G2FS; Fig. 1 A,C), while the major glycoforms registered for anti-HPA-1a IgG1, often ( Fig. 1D ), but not always (Fig. 1B) , lacked core fucose (G1, G2 and G2S;). One person showed high degrees of fucosylation for total IgG1 (97%; A) and anti-HPA-1a IgG1 (86%; B). The other also showed a high degree of fucosylation for total IgG1 (86%; C), yet a low degree of fucosylation for anti-HPA1a IgG1 (9%; D). Major fucosylated glycoforms are labeled in red, and non-fucosylated glycoforms are labeled in blue or unlabeled. Blue square, N-acetylglucosamine; red triangle, fucose; green circle, mannose; yellow circle, galactose; purple diamond, N-acetylneuraminic acid; pep, peptide moiety; asterisk, contaminant. Triple protonated glycopeptide signals were observed throughout. For the assignment of the glycopeptides signals see Table 1 . The level of galactosylation, sialylation, bisection (bisecting N-acetylglucosamine) and fucosylation were calculated according to the following formulas: Galactosylation = (G1F + G1FN + G1FS + G1FNS + G1) * 0.5 + G2F + G2FN + G2FS + G2FNS + G2 + G2S. Agalactosylated structures = G0F +G0FN +G0. Digalactosylated structures = G2F + G2FN + G2FS + G2FNS + G2 + G2S. Sialylation = G1FS + G2FS + G1FNS + G2FNS + G2S. Bisection = G0FN + G1FN + G2FN + G1FNS + G2FNS. Fucosylation = G0F + G1F + G2F + G0FN + G1FN + G2FN + G1FS + G2FS.
antibodies in HEK-293F FreeStyle cells in the absence or presence of 2F, which has recently been described to deplete the level of guanosine diphosphate fucose, the substrate of fucosyltransferases, and thereby prevent fucose incorporation into proteins. 36 In agreement with those results, addition of 100, 200, and 400 mM resulted in a dramatic reduction of core fucose incorporation into IgG, dropping from 76% fucosylation to 14%, 8%, and 6%, respectively (supplemental Figure 4) . For the following experiments, the 76% fucosylated sample was used as anti-TNP high fucose, and the 6% fucosylated sample was used as anti-TNP low fucose. In accordance with the unique presence of Asn162 in the human FcgRIII family, required for glycan-glycan interaction of IgG and FcgR, 5 we observed Figure 1 . Mass spectrometric analysis of Fc glycopeptides of total IgG1 and anti-HPA-1a IgG1 from 2 pregnant women. One person showed high degrees of fucosylation for total IgG1 (97%; A) and anti-HPA-1a IgG1 (86%; B). The other also showed a high degree of fucosylation for total IgG1 (86%; C), yet a low degree of fucosylation for anti-HPA-1a IgG1 (9%; D). Major fucosylated glycoforms are labeled in red, and nonfucosylated glycoforms are labeled in blue or are unlabeled. Blue square indicates N-acetylglucosamine; red triangle, fucose; green circle, mannose; yellow circle, galactose; purple diamond, N-acetylneuraminic acid; pep, peptide moiety; and asterisk, contaminant. Triple-protonated glycopeptide signals were observed throughout. For the assignment of the glycopeptides signals, see Table 1 . The level of galactosylation, sialylation, bisection (bisecting N-acetylglucosamine), and fucosylation were calculated according to the following formulas:
Systematic analysis of the Fc-glycosylation with regard to galactosylation, sialylation, presence of bisecting GlcNAc (bisection) and fucosylation, comparing the glycosylation of total IgG1 with that of anti-HPA-1a IgG1 in a pair-wise manner, revealed a slight but significant increase in the levels of Fc galactosylation ( Fig. 2A) . Similar, but less pronounced increases were observed for Fc-sialylation (Fig. 2B) . As expected the level of sialylation correlated significantly with the level of galactosylation for both total IgG and specific HPA-1a antibodies ( Supplementary Fig. 1 ), as the galactosylated structures form the substrate for the sialyltransferase (See Table 1 , Fig.1 ). No significant differences were observed for the bisecting GlcNAc content of anti-HPA-1a antibodies compared to total serum IgG1 (Fig. 2C) . However, while total IgG1 contained normal level of core fucose at Asn297, the majority of anti-HPA-1a antibody samples showed an overrepresentation of IgG1 without fucose (Fig. 2D) . Relative expression levels of major IgG-Fc Asn-297 glycoforms for both total IgG1 (x-axis) and antigen-specific IgG1 (y-axis) for 48 FNAIT-anti-HPA-1a serum samples (A-D)., Serum populations were analyzed for Fc-galactosylation (A), sialylation (B), bisection (C) and fucosylation (D). The statistical outcome between two-tailed paired t-test analysis of total IgG1 Vs specific antibodies is listed in each panel. The diagonal, dotted line represents the equal ratio between total IgG1 and the specific antibody.
Maternal IgG samples were taken within a time range of weeks to years after delivery. But also samples that were taken a prolonged period after delivery (N=7), still demonstrated a lowered degree of anti-HPA-1a fucosylation (specific IgG1 fucosylation minus total IgG1 fucosylation, Fig. 3 ). The degree of anti-HPA-1a-Fc-fucosylation (specific IgG1 fucosylation minus total IgG1 fucosylation) is plotted against the time after delivery, for seven anti-HPA-1a FNAIT samples (period of 6 weeks to 7 years post-delivery).
We hypothesized that this skewing in the IgG response against platelets in FNAIT patients may also affect other glycosylation features than fucosylation. We therefore investigated whether the degree of anti-HPA-1a fucosylation correlates with the degree of bisection, galactosylation and sialylation. We observed a weak but significant positive correlation between anti-HPA1a fucosylation and bisection (R 2 : 0.112) and a negative correlation between anti-HPA-1a fucosylation and galactosylation (R 2 : 0.200), while there was no significant correlation between anti-HPA-1a fucosylation and sialylation ( Supplementary Fig. 2 ).
Fc-glycosylation of anti-HLA-antibodies
To investigate whether the skewing of glycosylation seen in anti-platelet responses during pregnancies was due to a general anti-platelet response, or due to anti-HPA-1a related response in pregnancy, we also investigated the IgG responses formed against platelets in sera of 13 RT-patients (lack of adequate post-transfusion platelet-count increments, in which anti-HLA antibodies are frequently implicated). Similar to the anti-platelet responses in FNAIT, we found the anti-HLA Fc galactosylation in RT to be increased compared to total serum IgG1 levels (Fig. 4A) . Unlike the FNAIT samples, no specific increases were observed for Fc sialylation (Fig. 4B) , and the bisecting GlcNAc content of the anti-HLA antibodies was significantly decreased (Fig. 4C) . Also, in contrast to the Fc-fucosylation of anti-HPA1a antibodies, the anti-HLA Fc-fucosylation did not show any changes compared to total serum IgG1 (Fig. 4D ). In addition, we investigated a FNAIT-anti-HPA-1a sample, which also contained anti-HLA antibodies. The anti-HPA-1a antibodies displayed a markedly lowered degree of fucosylation (43% as compared to 94% for total IgG1), while the anti-HLA antibodies from the same sample were not skewed in fucosylation (87%; Supplemental fig. 3 ). 
IgG with low Fc-fucose have increased binding affinity to FcγRIIIa and FcγRIIIb
To test the biological influence of the lowered Fc-fucosylation of IgG antibodies in the clearance of platelets, we produced TNP-specific antibodies in HEK 293 Freestyle cells in the absence or presence of 2-Fluoro-fucose (2F). 2F has recently been described to deplete the level of GDP-fucose, the substrate of fucosyltransferases, and thereby prevent fucose incorporation into proteins. 36 In agreement with those results, addition of 100, 200 and 400 µM resulted in 113 a dramatic reduction of core fucose incorporation into IgG, dropping from 76% fucosylation to 14%, 8% and 6%, respectively (Supplementary fig. 4 ). For following experiments the 76% fucosylated sample was used as anti-TNP high fucose, and the 6% fucosylated sample was used as anti-TNP low fucose. In accordance with the unique presence of Asn-162 in the human FcγRIII family, required for glycan-glycan interaction of IgG and FcγR, 5 we observed that the lack of core fucosylation dramatically increased the binding affinity to FcγRIIIa and FcγRIIIb but not FcγRIIa (Table 2) . 
Lack of IgG-core fucosylation increases platelet-phagocytosis
We next TNP-haptenized platelets, labelled them with pHrodo (only fluorescent in acid environment) and opsonized them with the anti-TNP antibody. For both PMN and CD16 + monocytes, expressing FcγRIIIb or FcγRIIIa, respectively, fucosylated antibodies resulted in low platelet ingestion, while low-fucosylated antibodies showed a significantly increased phagocytic response with both effector cell types (Fig. 5a-b) . However CD16 -monocytes showed no preference for low-or high-fucosylated antibodies for platelet phagocytosis, in accordance with their lack of FcγRIIIa expression (Fig. 5c) .
Phagocytosis was also performed using anti-HPA-1a antibodies from 7 FNAIT sera. Platelets were labelled with pHrodo and opsonized with 35 AU of anti-HPA-1a antibody derived from maternal FNAIT sera, and subjected to phagocytosis by PMN. The degree of phagocytosis correlated significantly with degree of anti-HPA-1a Fc-fucosylation (P=0.023, R 2 =0.590, Figure 5d ). 
A lowered anti-HPA-1a Fc-fucosylation correlates with decreased neonatal platelet counts and increased disease severity in FNAIT patients
We then investigated if core fucosylation of the HPA1a antibodies affected the disease outcome clinically. A significant correlation between neonatal platelet counts, obtained directly after delivery, and the degree of anti-HPA-1a fucosylation was found in the FNAIT patients, with lowered anti-HPA-1a-Fc-fucosylation corresponding to low neonatal platelet counts ( Fig. 6a , P:0.043, ρ=0.32). We also found a significant correlation between the degree of anti-HPA-1a fucosylation and the clinical disease severity directly after delivery (ranging from asymptomatic, to mild symptoms such as petechiae, to moderate symptoms including organ bleedings, to severe symptoms such as intracranial hemorrhages, Fig. 6b , P: 0.020, ρ=-0.377). A lowered degree of anti-HPA-1a fucosylation corresponded to more severe clinical disease severity, with all asymptomatic patients bearing high level of IgG-Fc core fucosylation (on average 85%, Fig. 6b ). 
Discussion
In this study we analyzed a large FNAIT serum cohort consisting of 48 serum samples, all containing anti-platelet alloantibodies formed during pregnancy and directed against the most common immunogenic alloantigen on platelets, the HPA-1a epitope of glycoprotein IIb/ IIIa. The glycosylation patterns of anti-HPA-1a IgG1 antibodies were compared to those of total IgG1 antibodies within the same individual and to anti-platelet antibodies formed after platelet transfusion in RT-patients with anti-HLA antibodies. Antigen-specific antibodies were affinity-purified using surface immobilized antigen, and the tryptic-Fc glycopeptides of the pathogenic IgG1 as well as of total IgG1 were analyzed by mass spectrometry. The Fcglycosylation patterns of both FNAIT and RT cohorts of anti-platelet or anti-HLA antibodies displayed a slight, but significant, increase in the level of galactosylation. Only in the FNAIT group, we found anti-GPIIIa-antibodies with a slight but significant increase in the level of sialylation, and only in the RT-patient group we found a slight decrease in the level of bisecting GlcNAc of the anti-HLA antibodies. The main difference between the patient groups was observed for core fucosylation, with the majority of the FNAIT patients with anti-HPA-1a specific antibodies showing a markedly lowered IgG1-Fc fucosylation in pregnancy (levels down to 10% fucosylation), a very atypical form of IgG-Fc glycosylation, with normal values being higher than 90%. 13;37 To our knowledge, a lowered fucosylation has only been found for HIV-specific antibodies in elite controllers of HIV infection, but unlike in our study, these also displayed agalactosylated-and asialylated glycans. 38 We further observed normal high levels of core fucosylation for anti-HLA class I antibodies (RT-patients), of which twelve of the thirteen patients were women who we cannot exclude to have been immunized already during a previous pregnancy. Our previous study also featured patients (N=2) with anti-HPA-1a antibodies (normally observed in FNAIT patients) formed after transfusion and they also did not display a skewing in core fucosylation. 32 As other glycosylation patterns were affected as well, we hypothesize that this kind of IgG response must be governed by the very settings under which these antibodies are formed: either the Th2-dominant features of pregnancies, 39 the anti-platelet response, the anti-HPA1a response, or a combination of these factors. We also investigated a FNAIT-anti-HPA-1a sample, which also contained anti-HLA antibodies, with lowered Fc-fucosylation for the anti-HPA-1a antibodies, but not for the anti-HLA antibodies. Together with the data on normal fucosylation of anti-HLA antibodies from the RT-patients, this further lends support to the hypothesis that other factors besides pregnancy are involved in this type of IgG-fucosylation.
Among the 48 FNAIT samples analyzed, 7 samples were taken in a period ranging from 6 weeks to 7 years after delivery, whilst all the other samples were taken within two days after delivery. Surprisingly, the lower levels of IgG-fucose (specific values of relative abundance minus total values) seemed to persist for a prolonged period after delivery, indicating that the type of IgG glycosylation acquired during the onset of the immune response, is a subject of imprinting or due to long-lived plasma cells.
The increased levels of specific galactosylation of antigen-specific IgG1 compared to total IgG1 in the cohorts with anti-HPA-1a-antibodies developed after pregnancies and anti-HLAantibodies in platelet transfused patients appear to be, to our knowledge, the first disease settings in which this phenomenon is described. A high degree of galactosylation has been found to negatively affect IgG half-life in mice, 40 suggesting that galactosylation may also influence the transport of IgG from mother to child because both half-life and transport of IgG is mainly mediated by the neonatal Fc-receptor FcRn. 41 However, no such skewing for IgG transport across the human placenta was found in our previous study, 42 in accordance with the fact that the Fc-glycans are not involved in binding to FcRn. 43 The increased levels of galactosylation and sialylation observed for the anti-HPA-1a antibodies in FNAIT might also enable a downregulation of the immune response, opposing the stimulatory effect caused by a decreased anti-HPA-1a fucosylation.
Various B-cell stimuli have been shown to modulate Fc glycosylation. Both the TLR9 ligand CpG oligodeoxynucleotide and IL-21 have been shown to increase Fc galactosylation and reduce bisecting GlcNAc levels. In contrast, all-trans retinoic acid decreases galactosylation and sialylation levels. 44 Recently, also T-cell independent B cell activation has been shown to induce immunosuppressive sialylated IgG antibodies in mouse models. 45 In the present study, we observed increased levels of galactosylation and lowered levels of fucosylation. This may perhaps be regulated via a higher expression of β4-galactosyltransferase and a downregulation of fucosyltransferase 8 (FUT8) in the anti-HPA-1a producing plasma cells in the FNAIT patients. For HIV-specific antibodies, which also displayed decreased fucosylation, FUT8 expression was found to be decreased in controllers and treated progressors compared to untreated progressors, while the expression of the fucosidase FUCA2, was found to be increased in controllers and untreated subjects. 38 Recently, the transcription factor Hepatocyte Nuclear Factor (HNF)1a and its downstream target HNF4a have been identified as transcriptional regulators of key fucosyltransferases and fucose biosynthesis genes. 46 However, the exact stimuli as well as the regulatory pathways have yet to be elucidated. Also, the degree of anti-HPA-1a fucosylation demonstrated a low but statistically significant positive correlation with the level of bisecting GlcNAc, as well as a negative correlation with the level of galactosylation. This indicates that the glycosylation of the IgG antibodies is dictated by the specific immune reaction, forming a differential spectrum of Fc glycosylated antibodies that depends on the nature of the immune response.
FcγRIIIa is expressed either with valine or phenylalanine at position 158, with the V variant showing a stronger affinity for IgG1 and IgG3. 47;48 The expression of the higher affinity form (V158) is associated with higher incidence of ITP, suggesting this receptor to be highly relevant for the clearance of platelets. 49 In FNAIT, the decreased Fc-fucosylation of anti-platelet alloantibodies most likely contributes to enhanced platelet phagocytosis via increased Fc receptor interaction, as we confirmed by biosensor analysis and by phagocytosis of platelets. The increased affinity was seen only for FcγRIIIa, expressed on a subset of monocytes, macrophages and NK cells, and FcγRIIIb, expressed on granulocytes, but not for other FcγR-receptor types, as these do not express the glycan found at position 162 only found in both FcγRIII types. 5 The glycan attached to Asn162 in FcγRIII has been shown to interact directly with the IgG-Fc glycan, which is critically influenced by the presence or absence of the core fucose. In the latter case, this also allows for binding of the Fc-protein moiety to FcγRIII, which does not take place when fucose is present. 5 In accordance, both neutrophils and FcγRIII + (~5% of peripheral) monocytes showed strong phagocytosis only with low-fucosylated IgG, while FcγRIII --monocytes, the majority of monocytes in peripheral blood, showed no preference for platelets opsonized with either highly-or low-fucosylated antibodies. In addition, we found the degree of FNAIT-anti-HPA-1a Fc-fucosylation to correlate significantly with the degree of platelet-phagocytosis, with sera containing less core fucosylation in their anti-HPA1a antibodies giving rise to stronger phagocytosis. In line with this, we also found the degree of anti-HPA-1a Fc-fucosylation to correlate positively with neonatal platelet counts directly after delivery.
The association of the functional SNP within FcγRIIIa with the higher incidence of ITP, which fits with data demonstrating that the spleen is the most important site for IgG-opsonized platelet clearance by residing splenic macrophages and/or monocytes (that uniformly express FcγRIIIa). This suggests fucosylation of anti-platelet antibodies to play an important role. In support of this, we found anti-HPA-1a Fc-fucosylation levels to correlate negatively with the clinical disease severity in FNAIT. Although our FNAIT cohort is limited by the fact that most asymptomatic anti-HPA-1a patients remain undiagnosed, our study did include few patients who where asymptomatic directly after delivery. All of these asymptomatic patients demonstrated high levels of anti-HPA-1a Fc-fucosylation. Fucosylation-status of anti-platelet antibodies may therefore prove to be a useful diagnostic marker to evaluate disease severity. However, and perhaps somewhat remarkably, the function of the anti-HLA antibodies from RT-patients, all with normal fucosylation, seem less affected by their fucosylation as they apparently are fully capable of causing potent platelet destruction. However, other factors, such as titer, should also be taken into account, but also the FcγR most strongly involved in the destruction. For anti HPA-1a antibodies this appears to be FcγRIIIa, function of which is highly sensitive to core fucosylation, but for anti-HLA-class I antibodies this may be a different FcγR not sensitive for changes in core fucosylation.
In conclusion, the Fc glycosylation of anti-platelet antibodies in FNAIT and RT are associated with a slightly increased level of Fc galactosylation that predisposes the IgG for further modification by the addition of sialic acid. In FNAIT, an additional IgG modification frequently appears in the form of a very pronounced decrease of Fc-fucosylation, resulting in increased binding affinity to FcγRIIIa and FcγRIIIb as well as increased platelet-phagocytosis by PMN or FcγRIIIa + monocytes. This is also reflected by the positive correlation between the degree of anti-HPA-1a Fc-fucosylation and the neonatal platelet counts in FNAIT. In addition, lowered anti-HPA-1a Fc-fucosylation degree correlated significantly with more severe bleeding tendency. In contrast, we do not see this decreased fucosylation phenomenon for anti-HLA antibodies in RT, strongly suggesting that IgG glycosylation, and therefore its functional potential, is under a tight regulation in humans.
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Supporting Information Supplementary methods
Purification of anti-platelet antibodies from sera PAK12 plates were prewashed with wash buffer (GTI Diagnostics). For the purification of anti-HPA-1a antibodies, 50 µl sample diluent (GTI Diagnostics) and 50 µl serum sample were added to each well coated with the relevant antigen, which is GPIIb/IIIa for anti-HPA-1a alloantibodies. For the purification of these antibodies single wells coated with the relevant antigen were used, resulting in sufficient IgG quantities for mass spectrometric profiling. As a negative control, sample diluent and serum were likewise added to uncoated wells. For the purification of anti-HLA antibodies from refractory thrombocytopenia patients, samples were applied to HLA class I-coated wells, and as a negative control to wells coated with the irrelevant protein GPIb/IX of the PAK12 plate. Single wells coated with the relevant antigen were used for these purification, resulting in sufficient IgG for mass spectrometric profiling. When indicated, the purification of anti-HLA class I antibodies from the serum of an FNAIT patient, sera were applied to four HLA class I-coated wells in parallel and to 4 control wells. After an incubation of 1 hour at room temperature with gentle agitation, wells were washed three times with 300 µl wash buffer and 2x with 300 µl 25 mM ammonium bicarbonate. For the elution of bound antibodies, 100 µl 100 mM formic acid was added followed by 5 min of shaking. For the FNAIT patient for which serum incubations on anti-HLA class I-coated wells was performed in quadruplicate, the eluates were pooled, as were the eluates of the corresponding control wells, in order to obtain sufficient amounts of IgG1 antibodies for mass spectrometric analysis. Eluates were transferred to V-bottom plates and dried by vacuum centrifugation. Total IgG was prepared from 2 µl of serum using Protein G affinity purification in 96-well filter plates as described previously. 50 For proteolytic cleavage the dried eluates were dissolved in 20 µl 25 mM ammonium bicarbonate followed by 10 min of shaking. Freshly prepared trypsin (200 ng; sequencing grade; Promega, Leiden, The Netherlands) in 25 mM ammonium bicarbonate was added, followed by 10 min shaking. Samples were incubated overnight at 37°C, and stored at -20°C until usage.
Mass spectrometric IgG Fc glycosylation analysis
Nano liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed using an Ultimate 3000 RSLC nanoLC system (Thermo Scientific, Sunnyvale, CA). Aliquots of the tryptic digests of total IgG (0.2 µl) and anti-HPA-1a antibodies, anti-HLA antibodies and antiGPIIb/IIIa autoantibodies (10 μl) were applied to a C 18 PepMap TM 100 µm x 20 mm trapping column (5 µm, 100 Å; Thermo Scientific) and washed with 100% A (0.1% formic acid in water) at 15 µl/min for 2 min. Following valve switching, tryptic (glyco-)peptides were separated on a reverse-phase column (Acclaim C 18 PepMap; 75 µm×150 mm, 2 µm, 100 Å; Thermo Scientific) at a flow rate of 500 nl/min. The gradient applied was as follows: 0-25% eluent B (95% acetonitrile, 5% water) in 15 min and 25-70% eluent B in the next 10 min, followed by an isocratic elution with 70% eluent B for 5 min. The LC system was coupled via an online nanospray source to an Esquire HCT ultra ESI-ion trap-MS (Bruker Daltonics, Bremen, Germany) operated in the positive ion mode. For electrospray (1100-1250 V), stainless steel capillaries with an inner diameter of 30 μm (Proxeon, Odense, Denmark) were used. The solvent was evaporated at 170°C employing a nitrogen stream of 7 l/min. Ions from m/z 600 to m/z 1800 were registered. For glycosylation profiling, the mass spectrometer was used in the MS mode, while additional runs were performed in the auto-MS/MS mode for confirming glycopeptide identities. The HPLC method resulted in a resolution of the glycopeptides based on the peptide moiety with IgG1 glycopeptides eluting first, followed by IgG4 and IgG2 and 3 glycopeptides.
13;32;51 Moreover, glycopeptides with neutral glycan moieties tended to elute earlier than glycopeptides with antennae sialylation, as described before. 51 For both the neutral and the acidic glycopeptides of each IgG subclass, average mass spectra were generated over a 0.6 min elution range. Glycopeptides were assigned on the basis of mass, elution position and CID fragmentation pattern (Table 1) On the basis of the normalized intensities of IgG1 Fc glycopeptides the levels of galactosylation, sialylation, bisection (bisecting N-acetylglucosamine) and fucosylation were calculated according to the following formulas: Galactosylation = (G1F + G1FN + G1FS + G1FNS + G1) * 0.5 + G2F + G2FN + G2FS + G2FNS + G2 + G2S. Agalactosylated structures = G0F +G0FN +G0. Digalactosylated structures = G2F + G2FN + G2FS + G2FNS + G2 + G2S. Sialylation = G1FS + G2FS + G1FNS + G2FNS + G2S. Bisection = G0FN + G1FN + G2FN + G1FNS + G2FNS. Fucosylation = G0F + G1F + G2F + G0FN + G1FN + G2FN + G1FS + G2FS.
Surface Plasmon Resonance (SPR)
The Kd value was measured at the equilibrium state for different concentrations of ligand (fucose or low fucose IgG). The concentrations of IgG (fucose and low fucose IgG) binding to CD16a were: 0. Cell isolations and platelet haptenization with TNP Human platelets were freshly isolated form a buffy coat (Sanquin, Amsterdam, The Netherlands) using platelet-rich plasma (PRP), obtained after centrifugation at 400 g for 10 minutes. The platelets were washed once in phosphate-buffered saline (PBS) containing EDTA as well as 100 ng/mL prostaglandin E1 (PGE1, Sigma-Aldrich) in order to minimize activation. Platelets were brought to a concentration of 1*10 8 /ml PBS. Human PMN were isolated from peripheral blood obtained from healthy volunteers using a Ficoll 1.077 density gradient (GE Healthcare, Uppsala, Sweden) followed by hypotonic lysis of residual red blood cells on ice for several minutes. CD16 + (FcγRIIIa) monocytes were isolated from a buffy coat, lymphocyte-depleted using CD3-and CD19-microbeads (Miltenyi Biotech, Leiden, The Netherlands), via labeling with anti-human CD16 IgG2a antibody GRM1, using isotype anti-TNP IgG2a antibody as a negative control, and with both antibodies conjugated to Pacific Blue. Conjugation to Pacific Blue was performed by using the DyLight 405 Amine-Reactive Dye (Thermo Scientific, Waltham, MA), according to the manufacturer's protocol. Subsequently, CD16
+ as well as CD16 -monocytes were separated and purified on a FACSARIA II cell sorter (BD Biosciences, Erembodegem, Belgium). After platelet isolation, they were haptenized with TNP. For TNP haptenization of platelets, 1.66 µmol of 2,4,6-Trinitrobenzenesulfonic acid solution (TNBS, Sigma-Aldrich) dissolved in cacodylate buffer (Na(CH3)2 AsO2 • 3H2O, pH 6.9) was added to 1*108 platelets, incubated for 25 minutes at RT and subsequently washed with PBS/EDTA.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.01 (La Jolla, CA). Values of galactosylation, sialylation, bisecting and fucosylated structures of FNAIT samples were found to be normally distributed (D' Agostino-Pearson test) and, therefore, parametric testing was applied. Two-tailed, paired t-test was used to compare glycosylation of total IgG1 to specific IgG1. Analysis of correlations was performed using Pearson or Spearman correlation. SPR analysis was performed using a one-tailed paired t-test. Multiple comparisons were analyzed with a one-way ANOVA using Tukey's post-test. Level of significance was set at p<0.05.
